Skip to main content

Glaukos Corporation

corporate_fare Company Profile

Glaukos Corporation

GKOS·NYSE·Industrial Applications And Services·CIK 0001192448

Glaukos is an ophthalmic pharmaceutical and medical technology company that develops and sells dropless therapies for glaucoma, corneal disorders, and retinal disease. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and launched its first MIGS device, the iStent, commercially in 2012. In 2024, Glaukos began selling iDose® TR, a long-duration, intracameral procedural pharmaceutical implant that continuously delivers glaucoma drug therapy inside the eye. The company also provides proprietary bio-activated pharmaceutical therapies for corneal disorders. Glaukos's commercial and development-stage solutions for eye care professionals include procedural pharmaceuticals that use intracameral drug delivery to reduce intraocular pressure (IOP) by delivering glaucoma medication from inside the eye over time. They also offer MIGS products, which involve inserting a micro-scale device to reduce IOP by restoring natural aqueous humor outflow for glaucoma patients. Additionally, Glaukos provides bio-activated pharmaceuticals designed to strengthen, stabilize, and reshape the cornea for patients with corneal ectatic disorders like keratoconus, and transdermal pharmaceuticals applied to the eyelid for conditions such as demodex blepharitis and myopia.

Glaukos Corporation (NYSE:GKOS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 17 items for GKOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for GKOS spans 10-Q, 8-K, 144, 10-K.

Recent high-impact activity:

  • Glaukos 10-Q Confirms Q3 Sales of $211.0M (+58%) and First Quarterly Profit of $2.0M
  • Glaukos Beats with $211M Q3 Sales, Raises 2026 Guidance to $775-785M and Sets $1B 2027 Target
  • Glaukos Posts $211M in Third-Quarter Sales
  • iDose TR Beats Cataract Surgery Alone in Phase 4, Cutting IOP by 3.6 mmHg More
  • Insider Sale Sends Glaukos Down 13% Despite Positive Epioxa Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$507.44M
Net Income
-$187.69M
Diluted EPS
-$3.28
Op. Cash Flow
-$14.79M
Free Cash Flow
-$22.45M
Gross Profit
$282.76M
Operating Income
-$199.6M
Cash & Equivalents
$90.81M
Debt / Equity
0.00×
Net Margin
-37.0%
Shares Outstanding
57.51M sh
Source: 10-K · filed 2026-02-21 · accession 0001193125-26-061944

Short Interest & Short Volume

2.85 days to cover

FINRA reported short interest of 4,483,891 shares in GKOS as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 46.4% of GKOS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,483,891 shares as of October 30, 2026
Change vs prior period▲ 3.2%
Days to cover2.85 at avg daily volume of 1,575,473
Daily short volume (FINRA facilities)46.4% of 412,063 shares on November 20, 2026
5-day average short volume49.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$237.31
52-week range · as of 2026-10-28 $73.16 – $237.31
Market cap
$14.05B
Volume
1.1M (0.7× avg)
3-mo avg 1.6M
Live data · 2026-11-22 04:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GKOS - Latest Insights

GKOS
Oct 28, 2026, 5:22 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $215.00
Real-time Price: $237.31 info
Change: +$22.31 (+10%) info
Market Cap: $14.048B info
GKOS
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $196.05
Real-time Price: $237.31 info
Change: +$41.26 (+21%) info
Market Cap: $14.048B info
GKOS
Oct 28, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $181.43
Real-time Price: $237.31 info
Change: +$55.88 (+31%) info
Market Cap: $14.048B info
GKOS
Oct 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $161.29
Real-time Price: $237.31 info
Change: +$76.02 (+47%) info
Market Cap: $14.048B info
GKOS
Oct 08, 2026, 11:09 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $153.16
Real-time Price: $237.31 info
Change: +$84.16 (+55%) info
Market Cap: $14.048B info
GKOS
Oct 08, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $173.55
Real-time Price: $237.31 info
Change: +$63.76 (+37%) info
Market Cap: $14.048B info
GKOS
Oct 07, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $172.18
Real-time Price: $237.31 info
Change: +$65.13 (+38%) info
Market Cap: $14.048B info
GKOS
Aug 11, 2026, 12:05 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $182.24
Real-time Price: $237.31 info
Change: +$55.07 (+30%) info
Market Cap: $14.048B info
GKOS
Jul 29, 2026, 5:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $175.60
Real-time Price: $237.31 info
Change: +$61.71 (+35%) info
Market Cap: $14.048B info
GKOS
Jul 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $178.00
Real-time Price: $237.31 info
Change: +$59.31 (+33%) info
Market Cap: $14.048B info
GKOS
Jul 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $173.00
Real-time Price: $237.31 info
Change: +$64.31 (+37%) info
Market Cap: $14.048B info
GKOS
Jul 27, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $153.59
Real-time Price: $237.31 info
Change: +$83.72 (+55%) info
Market Cap: $14.048B info
GKOS
Apr 30, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $126.50
Real-time Price: $237.31 info
Change: +$110.81 (+88%) info
Market Cap: $14.048B info
GKOS
Apr 29, 2026, 4:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $116.96
Real-time Price: $237.31 info
Change: +$120.35 (+103%) info
Market Cap: $14.048B info
GKOS
Feb 20, 2026, 7:54 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $120.27
Real-time Price: $237.31 info
Change: +$117.04 (+97%) info
Market Cap: $14.048B info
GKOS
Feb 17, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $106.00
Real-time Price: $237.31 info
Change: +$131.31 (+124%) info
Market Cap: $14.048B info
GKOS
Jan 13, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $96.97
Real-time Price: $237.31 info
Change: +$140.34 (+145%) info
Market Cap: $14.048B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets